Effects of Lipid Lowering Therapy Optimization by PCSK9 Inhibitors on Circulating CD34+ Cells and Pulse Wave Velocity in Familial Hypercholesterolemia Subjects without Atherosclerotic Cardiovascular Disease: Real-World Data from Two Lipid Units
Background: Circulating CD34+ progenitor cells (CD34+CPCs) are characterized by pronounced tissue regeneration activity. Dyslipidemic subjects seemed to have reduced CD34+CPCs, and statin therapy appeared to restore their levels. We aimed to evaluate the effects of PCSK9 inhibitors (PCSK9-i) on CD34...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/7/1715 |
| _version_ | 1827624575480889344 |
|---|---|
| author | Roberto Scicali Giuseppe Mandraffino Michele Scuruchi Alberto Lo Gullo Antonino Di Pino Viviana Ferrara Carmela Morace Caterina Oriana Aragona Giovanni Squadrito Francesco Purrello Salvatore Piro |
| author_facet | Roberto Scicali Giuseppe Mandraffino Michele Scuruchi Alberto Lo Gullo Antonino Di Pino Viviana Ferrara Carmela Morace Caterina Oriana Aragona Giovanni Squadrito Francesco Purrello Salvatore Piro |
| author_sort | Roberto Scicali |
| collection | DOAJ |
| description | Background: Circulating CD34+ progenitor cells (CD34+CPCs) are characterized by pronounced tissue regeneration activity. Dyslipidemic subjects seemed to have reduced CD34+CPCs, and statin therapy appeared to restore their levels. We aimed to evaluate the effects of PCSK9 inhibitors (PCSK9-i) on CD34+CPCs and pulse wave velocity (PWV) in a cohort of heterozygous familial hypercholesterolemia (HeFH) subjects. Methods: We determined CD34+ cell count and its change after PCSK9-i in 30 selected HeFH subjects and 30 healthy controls. Lipid profile and PWV were evaluated at baseline (T0), 6 months after intensive lipid lowering strategy (statin plus ezetimibe, T1), and after 6 months of optimized therapy with PCSK9-i (T2); CD34+ cell count was reported at T1 and T2. Results: At T1, the median value of CD34+ cells was not significantly different between HeFH subjects and controls, and the same result was obtained at T2. PWV was significantly reduced at T1 (ΔPWV − 14.8%, <i>p</i> < 0.001 vs. T0) and T2 (ΔPWV − 10.96%, <i>p</i> < 0.001 vs. T1). Dividing HeFH subjects into two groups of high- and low-CD34+ cell count, CD34+CPCs appeared to be polarized with a significant difference between the two groups (1.2 (0.46) vs. 4.74 (1.92), <i>p</i> < 0.001), also with respect to controls (both <i>p</i> < 0.001). This polarization was no longer observed at T2, and neither with respect to controls. ΔCD34+ was +67.4% in the low-CD34+ group and −39.24% in the high-CD34+ group (<i>p</i> < 0.001). Lastly, we found a significant correlation between ΔCD34+ cell number and ΔPWV in HeFH subjects (rho = −0.365, <i>p</i> < 0.05), particularly in the low-CD34+ group (rho = −0.681, <i>p</i> < 0.001). Conclusion: PCSK9-i exhibited favorable effects on CD34 + CPCs as was on PWV values in a cohort of FH subjects. Our preliminary findings suggest a possible positive role of this novel lipid-lowering strategy on vascular homeostasis. |
| first_indexed | 2024-03-09T12:11:36Z |
| format | Article |
| id | doaj.art-3e903c19518a4177b3f4a5bfba193132 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T12:11:36Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-3e903c19518a4177b3f4a5bfba1931322023-11-30T22:51:25ZengMDPI AGBiomedicines2227-90592022-07-01107171510.3390/biomedicines10071715Effects of Lipid Lowering Therapy Optimization by PCSK9 Inhibitors on Circulating CD34+ Cells and Pulse Wave Velocity in Familial Hypercholesterolemia Subjects without Atherosclerotic Cardiovascular Disease: Real-World Data from Two Lipid UnitsRoberto Scicali0Giuseppe Mandraffino1Michele Scuruchi2Alberto Lo Gullo3Antonino Di Pino4Viviana Ferrara5Carmela Morace6Caterina Oriana Aragona7Giovanni Squadrito8Francesco Purrello9Salvatore Piro10Department of Clinical and Experimental Medicine, University of Catania, 95100 Catania, ItalyDepartment of Clinical and Experimental Medicine, University of Messina, University Hospital G. Martino, Lipid Center, 98100 Messina, ItalyDepartment of Clinical and Experimental Medicine, University of Messina, University Hospital G. Martino, Lipid Center, 98100 Messina, ItalyUnit of Rheumatology, Department of Medicine, ARNAS Garibaldi Hospital, 95100 Catania, ItalyDepartment of Clinical and Experimental Medicine, University of Catania, 95100 Catania, ItalyDepartment of Clinical and Experimental Medicine, University of Catania, 95100 Catania, ItalyDepartment of Clinical and Experimental Medicine, University of Messina, University Hospital G. Martino, Lipid Center, 98100 Messina, ItalyDepartment of Clinical and Experimental Medicine, University of Messina, University Hospital G. Martino, Lipid Center, 98100 Messina, ItalyDepartment of Clinical and Experimental Medicine, University of Messina, University Hospital G. Martino, Lipid Center, 98100 Messina, ItalyDepartment of Clinical and Experimental Medicine, University of Catania, 95100 Catania, ItalyDepartment of Clinical and Experimental Medicine, University of Catania, 95100 Catania, ItalyBackground: Circulating CD34+ progenitor cells (CD34+CPCs) are characterized by pronounced tissue regeneration activity. Dyslipidemic subjects seemed to have reduced CD34+CPCs, and statin therapy appeared to restore their levels. We aimed to evaluate the effects of PCSK9 inhibitors (PCSK9-i) on CD34+CPCs and pulse wave velocity (PWV) in a cohort of heterozygous familial hypercholesterolemia (HeFH) subjects. Methods: We determined CD34+ cell count and its change after PCSK9-i in 30 selected HeFH subjects and 30 healthy controls. Lipid profile and PWV were evaluated at baseline (T0), 6 months after intensive lipid lowering strategy (statin plus ezetimibe, T1), and after 6 months of optimized therapy with PCSK9-i (T2); CD34+ cell count was reported at T1 and T2. Results: At T1, the median value of CD34+ cells was not significantly different between HeFH subjects and controls, and the same result was obtained at T2. PWV was significantly reduced at T1 (ΔPWV − 14.8%, <i>p</i> < 0.001 vs. T0) and T2 (ΔPWV − 10.96%, <i>p</i> < 0.001 vs. T1). Dividing HeFH subjects into two groups of high- and low-CD34+ cell count, CD34+CPCs appeared to be polarized with a significant difference between the two groups (1.2 (0.46) vs. 4.74 (1.92), <i>p</i> < 0.001), also with respect to controls (both <i>p</i> < 0.001). This polarization was no longer observed at T2, and neither with respect to controls. ΔCD34+ was +67.4% in the low-CD34+ group and −39.24% in the high-CD34+ group (<i>p</i> < 0.001). Lastly, we found a significant correlation between ΔCD34+ cell number and ΔPWV in HeFH subjects (rho = −0.365, <i>p</i> < 0.05), particularly in the low-CD34+ group (rho = −0.681, <i>p</i> < 0.001). Conclusion: PCSK9-i exhibited favorable effects on CD34 + CPCs as was on PWV values in a cohort of FH subjects. Our preliminary findings suggest a possible positive role of this novel lipid-lowering strategy on vascular homeostasis.https://www.mdpi.com/2227-9059/10/7/1715circulating CD34+ cellsfamilial hypercholesterolemiaPCSK9 inhibitorspulse wave velocitycardiovascular risk |
| spellingShingle | Roberto Scicali Giuseppe Mandraffino Michele Scuruchi Alberto Lo Gullo Antonino Di Pino Viviana Ferrara Carmela Morace Caterina Oriana Aragona Giovanni Squadrito Francesco Purrello Salvatore Piro Effects of Lipid Lowering Therapy Optimization by PCSK9 Inhibitors on Circulating CD34+ Cells and Pulse Wave Velocity in Familial Hypercholesterolemia Subjects without Atherosclerotic Cardiovascular Disease: Real-World Data from Two Lipid Units Biomedicines circulating CD34+ cells familial hypercholesterolemia PCSK9 inhibitors pulse wave velocity cardiovascular risk |
| title | Effects of Lipid Lowering Therapy Optimization by PCSK9 Inhibitors on Circulating CD34+ Cells and Pulse Wave Velocity in Familial Hypercholesterolemia Subjects without Atherosclerotic Cardiovascular Disease: Real-World Data from Two Lipid Units |
| title_full | Effects of Lipid Lowering Therapy Optimization by PCSK9 Inhibitors on Circulating CD34+ Cells and Pulse Wave Velocity in Familial Hypercholesterolemia Subjects without Atherosclerotic Cardiovascular Disease: Real-World Data from Two Lipid Units |
| title_fullStr | Effects of Lipid Lowering Therapy Optimization by PCSK9 Inhibitors on Circulating CD34+ Cells and Pulse Wave Velocity in Familial Hypercholesterolemia Subjects without Atherosclerotic Cardiovascular Disease: Real-World Data from Two Lipid Units |
| title_full_unstemmed | Effects of Lipid Lowering Therapy Optimization by PCSK9 Inhibitors on Circulating CD34+ Cells and Pulse Wave Velocity in Familial Hypercholesterolemia Subjects without Atherosclerotic Cardiovascular Disease: Real-World Data from Two Lipid Units |
| title_short | Effects of Lipid Lowering Therapy Optimization by PCSK9 Inhibitors on Circulating CD34+ Cells and Pulse Wave Velocity in Familial Hypercholesterolemia Subjects without Atherosclerotic Cardiovascular Disease: Real-World Data from Two Lipid Units |
| title_sort | effects of lipid lowering therapy optimization by pcsk9 inhibitors on circulating cd34 cells and pulse wave velocity in familial hypercholesterolemia subjects without atherosclerotic cardiovascular disease real world data from two lipid units |
| topic | circulating CD34+ cells familial hypercholesterolemia PCSK9 inhibitors pulse wave velocity cardiovascular risk |
| url | https://www.mdpi.com/2227-9059/10/7/1715 |
| work_keys_str_mv | AT robertoscicali effectsoflipidloweringtherapyoptimizationbypcsk9inhibitorsoncirculatingcd34cellsandpulsewavevelocityinfamilialhypercholesterolemiasubjectswithoutatheroscleroticcardiovasculardiseaserealworlddatafromtwolipidunits AT giuseppemandraffino effectsoflipidloweringtherapyoptimizationbypcsk9inhibitorsoncirculatingcd34cellsandpulsewavevelocityinfamilialhypercholesterolemiasubjectswithoutatheroscleroticcardiovasculardiseaserealworlddatafromtwolipidunits AT michelescuruchi effectsoflipidloweringtherapyoptimizationbypcsk9inhibitorsoncirculatingcd34cellsandpulsewavevelocityinfamilialhypercholesterolemiasubjectswithoutatheroscleroticcardiovasculardiseaserealworlddatafromtwolipidunits AT albertologullo effectsoflipidloweringtherapyoptimizationbypcsk9inhibitorsoncirculatingcd34cellsandpulsewavevelocityinfamilialhypercholesterolemiasubjectswithoutatheroscleroticcardiovasculardiseaserealworlddatafromtwolipidunits AT antoninodipino effectsoflipidloweringtherapyoptimizationbypcsk9inhibitorsoncirculatingcd34cellsandpulsewavevelocityinfamilialhypercholesterolemiasubjectswithoutatheroscleroticcardiovasculardiseaserealworlddatafromtwolipidunits AT vivianaferrara effectsoflipidloweringtherapyoptimizationbypcsk9inhibitorsoncirculatingcd34cellsandpulsewavevelocityinfamilialhypercholesterolemiasubjectswithoutatheroscleroticcardiovasculardiseaserealworlddatafromtwolipidunits AT carmelamorace effectsoflipidloweringtherapyoptimizationbypcsk9inhibitorsoncirculatingcd34cellsandpulsewavevelocityinfamilialhypercholesterolemiasubjectswithoutatheroscleroticcardiovasculardiseaserealworlddatafromtwolipidunits AT caterinaorianaaragona effectsoflipidloweringtherapyoptimizationbypcsk9inhibitorsoncirculatingcd34cellsandpulsewavevelocityinfamilialhypercholesterolemiasubjectswithoutatheroscleroticcardiovasculardiseaserealworlddatafromtwolipidunits AT giovannisquadrito effectsoflipidloweringtherapyoptimizationbypcsk9inhibitorsoncirculatingcd34cellsandpulsewavevelocityinfamilialhypercholesterolemiasubjectswithoutatheroscleroticcardiovasculardiseaserealworlddatafromtwolipidunits AT francescopurrello effectsoflipidloweringtherapyoptimizationbypcsk9inhibitorsoncirculatingcd34cellsandpulsewavevelocityinfamilialhypercholesterolemiasubjectswithoutatheroscleroticcardiovasculardiseaserealworlddatafromtwolipidunits AT salvatorepiro effectsoflipidloweringtherapyoptimizationbypcsk9inhibitorsoncirculatingcd34cellsandpulsewavevelocityinfamilialhypercholesterolemiasubjectswithoutatheroscleroticcardiovasculardiseaserealworlddatafromtwolipidunits |